Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: selective androgen receptor modulators - GTx

Drug Profile

Research programme: selective androgen receptor modulators - GTx

Alternative Names: Andromustine; GTx 026; GTx-027; Libidarine; Prostarine

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GTx; Merck & Co
  • Developer GTx
  • Class Azasteroids; Benzamides; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • No development reported Breast cancer; Muscular atrophy

Most Recent Events

  • 22 Oct 2018 GTx plans a clinical trial for Prostate cancer in 2020
  • 22 Oct 2018 GTx plans IND-enabling studies for Prostate cancer in 2019
  • 28 Mar 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top